This technology licensing opportunity provides biosynthetic methods for the production of the antidiabetic drug voglibose. Briefly, antifungal validamycin A analogs, including 1,1′-bis-valienamine, are produced using valN mutant strains of Streptomyces organisms, such as Streptomyces hygroscopicus. The 1,1′-bis-valienamine product can be easily converted to valienamine, which in turn is converted to voglibose.
Features & Benefits
Background of Invention
Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Diabetes is a chronic, lifelong condition that often requires management with diabetes medications. It has been estimated that almost 30 million Americans, or 9.3% of the population, have diabetes, and diabetes remains the 7th leading cause of death in America. In order to combat the growing problem of diabetes and related healthcare costs, both new medications and more cost effective methods for manufacturing existing diabetes medications are needed.
Issued U.S. Patent 8,101,732